For example, patients with advanced hormone receptor-positive PIK3CA mutant breast cancer with inadequate ctDNA suppression on palbociclib and fulvestrant could benefit from early introduction of a PI3-kinase inhibitor. This evidence concerns the gene NR4A1 and breast carcinoma.